According to a new study published in the Journal of Clinical Oncology, second-line oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU) (OFF) significantly increased overall survival compared with leucovorin and 5-FU (FF) for advanced pancreatic cancer.
Deficiency impairs rituximab-mediated cellular cytotoxicity; substitution improves RMCC.
Para-aortic radiation with ≥36 Gy linked to increased risk of diabetes mellitus.
Pfizer will test Xalkori in hopes the combination will improve the outcomes for lung cancer patients.
A drug originally designed for killing a limited type of cancer cells could potentially be used to treat leukaemia.
Health sector prices explain much of difference between U.S. and other high-spending countries.
Millions signing up for Medicaid to comply with federal health care law.
Almost 80% of doctors in the United States have switched from paper to electronic health records.
Most physicians believe that doctors order too many medical tests, yet half admit to doing so themselves in response to a patient who insists, a new survey shows.
Several modifiable risk factors can cut chronic disease deaths over the next 15 years.
Caucasian women overestimate their risk of breast cancer while African American and Hispanic women underestimate their risk, according to research presented at BCS 2013.
A survey presented at BCS 2013 has found a number of factors that cause rural US women to avoid breast cancer screening.
The benefit of perioperative MRI for women with ductal carcinoma in situ (DCIS) is "uncertain," found a study presented during BCS 2013.
ChemotherapyAdvisor.com Editorial Board member Dr. Edith Perez of the Mayo Clinic, Jacksonville, FL, recommends high impact abstracts at the Breast Cancer Symposium 2013.
Women who underwent radiation for ductal carcinoma in situ do not face an increased risk of cardiovascular disease, found a study presented at BCS 2013.
Risk is greater in patients managed with watchful waiting than in those who undergo radical treatment.
Study shows a 3.5 times increased risk of death from renal cancer in hemodialysis patients undergoing nephrectomy.
In a study, none of the 62 men who had the treatment experienced erectile dysfunction or urinary incontinence.
Diffusion-weighted technique found to have a sensitivity and specificity of 89%-91% and 77%-81%, respectively.
In a study, the 12-year prostate cancer survival rate was 61.8% for men with the mutation versus 94.3% for those without it.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|